Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361

Autor: Alva, Ajjai, Csoszi, T., Özgüroğlu, Mustafa, Matsubara, N., Geczi, L., Cheng, S. Y-S., Powles, T. B.
Přispěvatelé: İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
Jazyk: angličtina
Rok vydání: 2020
Popis: ESMO Virtual Congress -- SEP 19-OCT 18, 2020 -- ELECTR NETWORK WOS:000573469102650 [No abstract available] European Soc Med Oncol Merck Sharp Dohme Corp.Merck & Company Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Databáze: OpenAIRE